Emperor preserved trial: Empagliflozin effective to treat heart failure
The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.
Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million. Several drugs are being investigated to manage heart failure.
The safety and efficacy of empagliflozin in patients with symptomatic heart failure was assessed in 2997 Patients randomized in a 1:1 design to either empagliflozin 10 mg or matching placebo of 2,991 patients in the trial.
Health-related quality of life in patients treated with empagliflozin had significant improvement in patients with meaningful improvements was reported in American College of Cardiology journal. Most routinely used drugs for Heart failure with reduced ejection fraction have not shown to be effective among patients, however this drug marks the change of treatment options.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.